Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV): a randomised, placebo-controlled, phase 2 crossover trial.

[1]  R. Wightman,et al.  What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio , 2020, Substance use & misuse.

[2]  M. Lock,et al.  Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis , 2020, Supportive Care in Cancer.

[3]  S. Bonaccorso,et al.  Cannabidiol (CBD) use in psychiatric disorders: A systematic. , 2019, Neurotoxicology.

[4]  I. McGregor,et al.  Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. , 2019, JAMA internal medicine.

[5]  T. England,et al.  A systematic review of cannabidiol dosing in clinical populations , 2019, British journal of clinical pharmacology.

[6]  M. Stockler,et al.  Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV) , 2018, BMJ Open.

[7]  E. Bruera,et al.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Wilkie,et al.  Medical Marijuana Use in Oncology: A Review. , 2016, JAMA oncology.

[9]  M. Aapro,et al.  Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[10]  J. Kramer.  Medical marijuana for cancer , 2015, CA: a cancer journal for clinicians.

[11]  Stephen Szabo,et al.  Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. , 2014, Journal of oncology practice.

[12]  J. Richardson,et al.  Validity and Reliability of the Assessment of Quality of Life (AQoL)-8D Multi-Attribute Utility Instrument , 2013, The Patient - Patient-Centered Outcomes Research.

[13]  A. Molassiotis,et al.  The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Pastor,et al.  Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. , 2010, British journal of clinical pharmacology.

[15]  R. Murray,et al.  Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.

[16]  A. Molassiotis,et al.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre , 2008, Supportive Care in Cancer.

[17]  R. Osborne,et al.  Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure , 2005, Australian and New Zealand journal of public health.

[18]  J. Pearson,et al.  Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.

[19]  M. Aapro.  Prevention of chemotherapy-induced nausea and vomiting in patients with cancer. , 1981, Arizona medicine.